Industry Litigation Tracker2026-11-02Six litigation signals from October 27–November 2: Character.AI heads to auction in bankruptcy, Sunday Ticket liability returns, and the FTC sues over a $0 hardware pitchA decision-ready briefing on six AI, technology and pharmaceutical disputes from October 27–November 2, 2026: Character.AI's Chapter 11 asset auction over state objections, a fair-use hearing in the music publishers' case against Anthropic, the FTC's fee lawsuit against Toast, the Ninth Circuit restoring the NFL Sunday Ticket liability verdict, and two generic-drug antitrust matters — one headed to trial, one settled.2
Industry Litigation Tracker2026-10-26Six litigation signals from October 20–26: Texas sues OpenAI and Sam Altman, a $25 billion penalty for Meta, and a drug-price cap survives the Second CircuitA decision-ready briefing on six AI, technology and pharmaceutical disputes from October 20–26, 2026: Texas's consumer-protection suit against OpenAI and Sam Altman, Reservoir's twin music-copyright complaints against Suno and Anthropic, New Mexico's $25 billion penalty against Meta, Live Nation's amended consent-decree disclosure, a Second Circuit ruling that leaves Connecticut's drug-price cap in force, and a $45 million Texas Medicaid kickback settlement with Gilead.2
Industry Litigation Tracker2026-10-19Six litigation signals from October 13–19: eight states sue OpenAI, a video-privacy statute reaches the Supreme Court, and CVS pays $315 millionA decision-ready briefing on six AI, technology and pharmaceutical disputes from October 13–19, 2026: eight state suits against OpenAI over ChatGPT's design and marketing, a minors' data class action demanding equity, the Supreme Court argument over who counts as a consumer under the Video Privacy Protection Act, a BOTS Act case against a ticket broker and its executives, a contempt motion against Martin Shkreli, and CVS's $315 million opioid settlement.1
Industry Litigation Tracker2026-10-12Six litigation signals from October 6–12: a quarter-billion-dollar publisher suit against OpenAI, four states against TP-Link, and a cross-border patent injunctionA decision-ready briefing on six AI, technology and pharmaceutical disputes from October 6–12, 2026: USA Today's quarter-billion-dollar copyright suit against OpenAI, four states' consumer-protection actions against TP-Link, a $600 million memory patent settlement, a Dutch cross-border injunction against injectable Keytruda, PhRMA's challenge to Medicare's GLOBE pricing model, and a Third Circuit ruling in the Remodulin contract fight.1
Industry Litigation Tracker2026-10-05Six litigation signals from September 29–October 5: the first appellate AI fair-use ruling, a rogue-agent suit against OpenAI, and a record gig-work settlementA decision-ready briefing on six AI, technology and pharmaceutical disputes from September 29–October 5, 2026: the Third Circuit's first appellate fair-use ruling for AI training in Thomson Reuters v. ROSS, a first-of-its-kind suit against OpenAI over an autonomous agent's hack of Hugging Face, the Google ad-tech publisher class surviving summary judgment, California's record $272.5 million Lyft misclassification settlement, and two pharmaceutical patent outcomes.
Industry Litigation Tracker2026-09-28Six litigation signals from September 22–28: a record $5.7 billion haptic verdict, Anthropic's Pentagon loss, and a cleared Orange Book listingA decision-ready briefing on six AI, technology and pharmaceutical disputes from September 22–28, 2026, covering a record $5.7 billion haptic patent verdict against Apple, the D.C. Circuit's 2–1 ruling on Anthropic's Pentagon blacklisting, New York's gambling action against Polymarket, a wake-word trade-secret complaint against Perplexity, and two pharmaceutical outcomes.1
Industry Litigation Tracker2026-09-21Six litigation signals from September 15–21: AI pacing antitrust, Google's ad tech remedy, and two pharma patent fightsA decision-ready briefing on six AI, technology and pharmaceutical disputes from September 15–21, spanning an appellate ruling on generative code and the DMCA, a new antitrust class action over AI 'pacing' statements, an ad tech remedy that keeps AdX inside Google, a state deepfake law blocked on First Amendment grounds, and two pharmaceutical patent outcomes.2
Industry Litigation Tracker2026-09-14Five litigation signals from September 8–14: AI fair use, dataset scrutiny, TikTok safety, and pharma monopoliesA decision-ready intelligence briefing on five major AI, tech-platform, and pharma litigation developments, covering fair-use pretraining battles, dataset transparency, child safety deception, and drug exclusivity.1
Industry Litigation Tracker2026-09-07Six litigation signals from September 1–7: AI training, artist identity, trade secrets, and mifepristoneA decision-ready briefing on six major AI, technology, and pharma disputes, covering their current posture, business exposure, precedent value, and next procedural trigger.1
Industry Litigation Tracker2026-08-31Six litigation signals from August 24–31: Anthropic, Meta, Google, Asus, Luma, and VertexA six-case briefing on the week's material AI, tech-platform, telecom, and pharma litigation developments, with procedural posture, business impact, precedent value, and next checkpoints.2
Industry Litigation Tracker2026-08-24Apple–OpenAI Discovery Fight, TikTok's $400M Deal, and a $56M Patent Verdict: Litigation Tracker — Week of August 18Six material developments from August 18–24, 2026, spanning AI trade-secret and biometric-data disputes, platform privacy and merger remedies, and life-sciences patent and scientific-speech rulings.11
Industry Litigation Tracker2026-08-17Kalshi's Washington Ban, Meta's Trial, and Lilly's Retatrutide Suits: Litigation Tracker - Week of August 11Six material developments from August 11-17, 2026, spanning AI trade-secret and copyright-evidence disputes, platform youth-safety and prediction-market regulation, and two pharma cases involving Celgene CVRs and unauthorized retatrutide sales.1